【正文】
in the European Union:medical management, epidemiology and economic Osteoporosis, 2020, 8 (12) :251258. [3]Compston J, Cooper A, Cooper C, et national osteoporosis guideline group (NOGG) , Arch Osteoporos, 2020, 12 (1) :43. [4]國(guó)家中醫(yī)藥管理局。中醫(yī)病癥指導(dǎo)療效標(biāo)準(zhǔn)。南京:南京大學(xué)出版社, 2020: TCM for curative effect of tcm :Nanjing University :186. (in Chinese)?! ?br /> [5]張俐。中醫(yī)骨病學(xué)。北京:人民衛(wèi)生出版社, 2020: of traditional chinese :People’s Health Press, 2020:61. (in Chinese)?! ?br /> [6]鄭筱萸。中藥新藥臨床研究指導(dǎo)原則。北京:中國(guó)醫(yī)藥科技出版社:2002: on the clinical research of new drugs in traditional chinese :China Medical Science and Technology Press, 2002:357. (in Chinese)?! ?br /> [7]李東濤, 王劍, 姜洪洋, 等。骨質(zhì)疏松癥常見(jiàn)中醫(yī)定性證候輕重程度量化評(píng)價(jià)。中西醫(yī)結(jié)合學(xué)報(bào), 2020, 10 (11) : DT, Wang J, Jiang HY, et evaluation of the mon Chinese medicine qualitative syndromes of of Chinese Integrative Medicine, 2020, 10 (11) :12541262. (in Chinese)?! ?br /> [8]秦集斌, 宋潔富, 薛旭紅。原發(fā)性骨質(zhì)疏松癥的病因?qū)W研究進(jìn)展。中國(guó)骨質(zhì)疏松雜志, 2020, 22 (4) : JB, Song JF, Xue progress of primary osteoporosis J Osteoporos, 2020, 22 (4) :511514. (in Chinese)?! ?br /> [9]袁明陽(yáng), 王建偉。中醫(yī)藥治療骨質(zhì)疏松癥的研究進(jìn)展。世界中醫(yī)藥, 2020, 11 (6) :11191121, MY, Wang progress of osteoporosis in Traditional Chinese Chinese Medicine, 2020, 11 (6) :11191121, 1125. (in Chinese)?! ?br /> [10]王柄棋, 孫雨晴, 陳翔, 等。絕經(jīng)后骨質(zhì)疏松癥藥物治療的現(xiàn)狀與思考。中國(guó)骨質(zhì)疏松雜志, 2020, 23 (6) : BQ, Sun YQ, Chen X, et status and thinking of postmenopausal osteoporosis treatment by J Osteoporos, 2020, 23 (6) :818823. (in Chinese)。此資料由網(wǎng)絡(luò)收集而來(lái),如有侵權(quán)請(qǐng)告知上傳者立即刪除。資料共分享,我們負(fù)責(zé)傳遞知